• Home
  • Privacy Policy
  • Terms & Conditions
  • Thank you
Profit News Report
No Result
View All Result
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
No Result
View All Result
Profit News Report
No Result
View All Result
Home Editor's Pick

Trump ends Biden’s drug price nightmare — Americans get real relief with TrumpRx

by
March 11, 2026
in Editor's Pick
0
Trump ends Biden’s drug price nightmare — Americans get real relief with TrumpRx
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

As a physician and a mother, I have seen firsthand how Washington’s decisions ripple into the exam room and around the kitchen table. At a time when healthcare debates often divide, it is worth recognizing leaders who safeguard freedom while tackling real health needs. The Trump administration is doing exactly that: protecting access, preserving choice and confronting public-health challenges while trusting families and their physicians to decide what is best.

President Donald Trump is proving that when Washington listens to everyday Americans and acts with urgency, real change is possible. For too long, the crushing cost of prescription drugs has forced families to make an impossible choice between filling a prescription and paying their bills.

Lowering drug prices has been a cornerstone of his presidency, and he has taken meaningful steps to deliver by expanding generics and biosimilars, implementing historic price transparency rules, capping insulin costs for seniors, advancing TrumpRX to increase competition to increase competition and direct access, and pursuing a ‘Most Favored Nation’ policy, so Americans are no longer paying more for medications than patients in other developed countries.

These policies represent an important shift toward putting patients, not middlemen, first. It’s a strong and necessary start, but sustaining this momentum by increasing competition and expanding access will be critical to finally bringing lasting relief to Americans.

This is not the first time Trump has revolutionized healthcare access. He set the tone during his first term with Operation Warp Speed, a milestone in American biomedical history, after COVID-19 paralyzed the world six years ago this month. By pairing private‑sector innovation with decisive federal coordination, it accelerated effective vaccine development and distribution; proving speed and rigor can coexist when government clears paths instead of creating bottlenecks. Just as important, it expanded options for patients and families, reinforcing a simple principle: access first, always.

What followed, however, is where public trust began to erode. Not because of Operation Warp Speed, but because its success was taken over by bureaucratic overreach. I watched in real time as public trust in health institutions collapsed, common sense was dismissed, legitimate debate was shut down and universal COVID vaccine mandates were imposed. Patients did not turn away from the vaccine recommendations because of the science; they turned away because of coercion despite evolving science and varying risk levels.

When personal autonomy gave way to mandates, they undermined confidence in both institutions and vaccines themselves. The result wasn’t the product of Trump’s leadership and scientific progress; it was the consequence of power being prioritized over personal choice.

Today, this administration is again pursuing strong public‑health outcomes without treating Americans as bystanders. Trust should be built where it matters most: in the home and in the doctor’s office. Parents want choice. Doctors want access. Parents overwhelmingly trust their own physicians. Doctors who know a child’s history and needs should remain the most trusted voices and, increasingly, America’s health agencies are speaking that same language.

The recent shift in tone from top health leaders is significant and worth recognizing. Acting Centers for Disease Control and Prevention Director Jay Bhattacharya is urging Americans to get the measles vaccine as cases rise and the U.S. risks losing its hard-won elimination status. He called the decision ‘deeply personal’ while making clear that ‘measles is preventable and vaccination remains the most effective way to protect yourself and those around you.’

Centers for Medicare & Medicaid Services Administrator Mehmet Oz echoed that in February: ‘There will never be a barrier to Americans getting access to the measles vaccine. It is part of the core schedule.’ This is what responsible public health communication looks like: honest, direct, and rooted in science, without coercion.

President Donald Trump is proving that when Washington listens to everyday Americans and acts with urgency, real change is possible.

The challenge now is sustaining this posture. Keeping vaccines available, affordable and accessible is not a concession to one side of the political debate, it’s broadly popular across the spectrum and conservatives are no exception. Skepticism of mandates and top-down health edicts does not translate into a desire to see vaccines become harder to get or more expensive to access. Americans want the freedom to make their own choices alongside their doctors and that freedom is only meaningful when access is guaranteed.

At the same time, the message must be clear: removing mandates does not mean vaccines are no longer recommended, or they have somehow been deemed unsafe. Vaccines remain one of the most effective tools in modern medicine. When vaccination rates fall, history and modern-day show that preventable disease and mortality rise.

Trump understands this, and his agencies need to hold the line: speak honestly about what the science says, respect personal decision-making and ensure that no American faces a barrier to a vaccine they want. That’s a winning posture politically — and more importantly, it’s the right thing to do.

This post appeared first on FOX NEWS
Previous Post

The US government targeted me for my political speech. It could happen to you, too

Next Post

Rheinmetall falls on earnings miss but Ukraine, Iran wars boost sales outlook

Next Post
Rheinmetall falls on earnings miss but Ukraine, Iran wars boost sales outlook

Rheinmetall falls on earnings miss but Ukraine, Iran wars boost sales outlook

  • Trending
  • Comments
  • Latest
Trump’s Fed Criticism Sparks Investor Concerns

Trump’s Fed Criticism Sparks Investor Concerns

April 22, 2025
A look back at Biden’s Remarkable 50-year career in politics

A look back at Biden’s Remarkable 50-year career in politics

March 20, 2025
UN Human Rights Council chief cuts off speaker criticizing US-sanctioned official

UN Human Rights Council chief cuts off speaker criticizing US-sanctioned official

February 28, 2026
Trump says he plans to order federal ban on Anthropic AI after company refuses Pentagon demands

Trump says he plans to order federal ban on Anthropic AI after company refuses Pentagon demands

February 28, 2026
Nvidia Stock Tumbles on Earnings Anticipation and AI Rivalry

Nvidia Stock Tumbles on Earnings Anticipation and AI Rivalry

0
The dollar index continues to pull back to a new low

The dollar index continues to pull back to a new low

0
BNGO Stock: BioNano Genomics Analysis and Forecast

BNGO Stock: BioNano Genomics Analysis and Forecast

0
Gold and Silver: Gold remains stable in the $2420 zone

Gold and Silver: Gold remains stable in the $2420 zone

0
Top FTSE 250 shares to watch: IG Group, Travis Perkins, Trustpilot

Top FTSE 250 shares to watch: IG Group, Travis Perkins, Trustpilot

March 13, 2026
Why are investors suing JPMorgan over a $328M crypto Ponzi case?

Why are investors suing JPMorgan over a $328M crypto Ponzi case?

March 13, 2026
Why Josh Brown sees Starbucks as ‘best stock in the market’

Why Josh Brown sees Starbucks as ‘best stock in the market’

March 13, 2026
Morning Brief: Asian stocks fall; Bitcoin jumps after US oil waiver

Morning Brief: Asian stocks fall; Bitcoin jumps after US oil waiver

March 13, 2026

Recent News

Top FTSE 250 shares to watch: IG Group, Travis Perkins, Trustpilot

Top FTSE 250 shares to watch: IG Group, Travis Perkins, Trustpilot

March 13, 2026
Why are investors suing JPMorgan over a $328M crypto Ponzi case?

Why are investors suing JPMorgan over a $328M crypto Ponzi case?

March 13, 2026
Why Josh Brown sees Starbucks as ‘best stock in the market’

Why Josh Brown sees Starbucks as ‘best stock in the market’

March 13, 2026
Morning Brief: Asian stocks fall; Bitcoin jumps after US oil waiver

Morning Brief: Asian stocks fall; Bitcoin jumps after US oil waiver

March 13, 2026
  • Privacy Policy
  • Terms & Conditions
  • Privacy Policy
  • Terms & Conditions

Disclaimer: Profitnewsreport.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Copyright © 2025 Profitnewsreport.com

No Result
View All Result
  • Home
  • Privacy Policy
  • Terms & Conditions
  • Thank you

Disclaimer: Profitnewsreport.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Copyright © 2025 Profitnewsreport.com